IMBRUVICA

April 5, 2019

Three-tiered Combination Stimulates Immune System to Attack Lymphoma Cells, Phase 1/2 Trial Shows

News

A combination of oral Imbruvica (ibrutinib), intratumoral CpG, and local low-dose radiation stimulates the immune system to safely and effectively attack lymphoma cells, according to a new study. The study, ... Read more

February 28, 2019

First Patient Dosed in Trial of ADCT-402/Imbruvica Combo for Advanced DLBCL, MCL

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imbruvica (ibrutinib) for advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) has dosed the first patient. Patient ... Read more

February 13, 2019February 14, 2020

X4 Pharmaceuticals Launches Phase 1b Trial Testing Mavorixafor-Imbruvica Combo for Waldenström’s Macroglobulinemia

News

X4 Pharmaceuticals has launched a Phase 1b trial to assess the safety and tolerability of mavorixafor (X4P-001), in combination with Imbruvica (ibrutinib), for the treatment of people with Waldenström’s macroglobulinemia ... Read more

January 31, 2019

FDA Approves Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has approved a combination of Imbruvica (ibrutinib) and Gazyva (obinutuzumab) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This is the first ... Read more

January 24, 2019

Imbruvica-Opdivo Combination Shows Promise in Richter’s Transformation

News

A combination of Imbruvica (ibrutinib) and Opdivo (nivolumab) reduced tumor burden in 65% of patients with Richter’s transformation — a kind of diffuse large B-cell lymphoma (DLBCL) with very poor prognosis, derived ... Read more

November 30, 2018

First Patient Dosed in Phase 3 Trial of BeiGene’s Zanubrutinib for Hard-to-Treat Leukemia, Lymphoma

News

The global Phase 3 trial evaluating BeiGene’s investigational Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has started dosing patients. The study (NCT03734016) is recruiting patients who failed ... Read more

August 28, 2018August 28, 2018

FDA Approves Imbruvica-Rituxan Combo Therapy for Rare Type of Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) plus Rituxan (rituximab) for the treatment of patients with a rare type of non-Hodgkin’s lymphoma called Waldenström’s macroglobulinemia (WM). This represents the first and only chemotherapy-free combination ... Read more

July 20, 2018

Adding Imbruvica to R-CHOP Does Not Improve Outcomes for Newly Diagnosed DLBCL Patients, Phase 3 Trial Shows

News

Adding Imbruvica (ibrutinib) to a standard chemotherapy regimen does not improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma (NHL), a Phase 3 trial ... Read more

June 12, 2018

Xynomic Pharma Plans 4 Clinical Trials of Abexinostat for Lymphoma

News

Xynomic Pharma announced it has completed a new Series B financing round and now will initiate eight clinical trials, four of which are for different types of lymphoma, in the next 12 ... Read more

June 8, 2018

Imbruvica-Rituxan Combo Significantly Delays Progression of Rare Type of Lymphoma in Phase 3 Trial

News

A combination of Imbruvica (ibrutinib) and Rituxan (rituximab) significantly extends the time to disease worsening or death in patients with a rare type of lymphoma called Waldenström’s macroglobulinemia, a Phase 3 trial ... Read more